Hormone replacement versus natural frozen embryo transfer for euploid embryos.

Frozen embryo transfer Hormone replacement frozen embryo transfer Medicated frozen embryo transfer Natural frozen embryo transfer Preimplantation genetic screening Preimplantation genetic testing for aneuploidies

Journal

Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213

Informations de publication

Date de publication:
10 2019
Historique:
received: 10 04 2019
accepted: 10 07 2019
pubmed: 25 7 2019
medline: 30 5 2020
entrez: 25 7 2019
Statut: ppublish

Résumé

The goal of this study is to investigate hormone replacement (HR) versus natural frozen embryo transfer outcomes for euploid embryos. This is a retrospective cohort study at an academic medical center of patients undergoing in vitro fertilization with 24-chromosome day 5/6 preimplantation genetic testing for aneuploidies (PGT-A), from 2014 to 2018 using euploid single embryo frozen transfer. Multivariable logistic regression was used to study the association between transfer outcomes (ongoing pregnancy and miscarriage) with type of frozen euploid embryo transfer (HR versus natural) while controlling for multiple patient and cycle confounders. From a total of 389 cycles, 45.0% utilized HR frozen embryo transfer and 55.0% were natural cycles. We found that when compared to HR frozen embryo transfer, natural cycle frozen embryo transfer had significantly higher ongoing pregnancy rates (aOR 2.05, 1.27-3.31, p = 0.003). There was no significant difference in miscarriage rates between the two groups (aOR for natural 0.69, 95% CI 0.37-1.32, p = 0.27). When limiting the analysis to only the first transfer at our institution, findings were similar of higher ongoing pregnancy rates and no difference in miscarriage rates. In our multivariate analysis, we found that natural cycle single euploid frozen embryo transfer was associated with significantly higher ongoing pregnancy rates than HR transfer, with no difference in miscarriage rates.

Identifiants

pubmed: 31338657
doi: 10.1007/s00404-019-05251-4
pii: 10.1007/s00404-019-05251-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1053-1060

Auteurs

Ange Wang (A)

Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, 94305, USA. angewang31@gmail.com.

Gayathree Murugappan (G)

Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Jonathan Kort (J)

Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Lynn Westphal (L)

Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA, 94305, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH